Logo Bocconi


Associate Professor
Department of Policy Analysis and Public Management

Personal page

Courses a.y. 2016/2017


Biographical note

Università Bocconi 1992, degree in Business Administration. MSc in Health Services Management with distinction at the University of London in 1996. PhD in Economics at the University of London in 2003.

Academic CV

Director, CERGAS, Bocconi University. Associate Professor of Management, Bocconi University.  SDA Professor, Public Management & Policy Department. 

Research areas

Economic evaluation analysis of healthcare programmes, health policy, healthcare management, health technology assessment, budget impact analysis and healthcare management.

Selected publications

Ciani O, Arendsen E, Romancik M, Lunik R, Costantini E, Di Biase M, Morgia G, FragalaÌ€ E, Roman T, Bernat M, Guazzoni G, Tarricone R, Lazzeri M. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) for the treatment of female recurrent urinary tract infections: a European multicenter nested case-control study. BMJ Open 2016;6:e009669. doi:10.1136/bmjopen-2015- 009669.

Armeni P, Boscolo PR, Tarricone R, Capodanno D, Maggioni A, Grasso C, Maisano F. Real-World Cost Effectiveness of Mitraclip combined with Medical Therapy Versus Medical Therapy Alone in Patients With Moderate or Severe Mitral Regurgitation. International Journal of Cardiology 2016; 209:153-160.

Rognoni C, Meregaglia M, Tarricone R, Efficacy and safety of iron supplementation in anaemic patients: a systematic review and meta-analysis of randomized controlled trials. Clinical Drug Investigations 2016; 36(3):177-194

Tarricone R, Medina Lara A, Abu Koush D. A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. Critical Reviews in Oncology/Hematology 2016; 99:37-48.

Tarricone R, Ricca G, Nyanzi-Wakholi B, Medina Lara A. Impact of cancer anorexia-Cachexia Syndrome on Health-Related Quality of Life and Resource Utilisation: a Systematic Review. Critical Reviews in Oncology/Hematology 2016; 99:49-62.

Sommariva S, Pongiglione B, Tarricone R. Impact of Chemotherapy- Induced Nausea and Vomiting on Health-Related Quality of Life and Resource Utilization: a Systematic Review. Critical Reviews in Oncology/Hematology 2016; 99: 13-36.

Valzania C, Torbica A, Tarricone R, Leyva F, Boriani G. Implant rates of cardiac implantable electrical devices in Europe: a systematic literature review. Health Policy 2016;120(1):1-15

Generali D, Venturini S, Rognoni C, Ciani R, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer. Breast Cancer Research and Treatment 2015;152(1):95-117.

Gonzales FM, Finch AP, Armeni P, Boscolo PR, Tarricone R. Comparative Effectiveness of Mitraclip versus Optimal Medical Therapy in High-Risk Surgical Patients: a Comprehensive Review. Expert Review of Medical Devices 2015;12(4): 471-485.

Beresniak A, Medina-Lara A, Auraye JP, Weverf A, Praetf JC, Tarricone R, Torbica A, Dupont D, Lamure M, Durue G. Validation of the underlining assumptions of the QALY outcome: results from the ECHOUTCOME European project. Pharmacoeconomics 2015;33(1):61-69.

Gehring M, Jommi C, Tarricone R, Cirenei M, Ambrosio G. Towards a More Competitive Italy in Clinical Research: The Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). Epidemiology, Biostatistics and Public Health 2015;12(1):1-9.

Tarricone R, Torbica A, Ferrè F, Drummond M. Generating Appropriate Clinical Data for Value Assessment of Medical Devices: What Role Does Regulation Play? Expert Review of Pharmacoeconomics and Outcome Research 2014;14(5):707-718.

A. Compagni, A. Melegaro, R. Tarricone. Genetic Screening for the Predisposition to Venous Thromboembolism: A Cost-Utility Analysis of Clinical Practice in the Italian HealthCare System. Value in Health 2013; 16: 909-921.

O Ciani, D Grassi, R Tarricone. An economic perspective on urinary tract infection: the "costs of resignation". Clinical Drug Investigation 2013; 33(4): 255-261

S. Calciolari, A. Torbica, R. Tarricone. Explaining the health costs associated with managing intracranial aneurysms in Italy. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 2013; 11(4): 427-435.

C. Salvatore, PR Boscolo, R. Tarricone. Planning and control of medical device investments by Italian public health authorities: A means to improve the decision-making process.  Journal of medical marketing 2013; 13(3): 135-141.

BD Smith, R. Tarricone, V. Vella. The role of product life cycle in medical technology innovation.  Journal of medical marketing 2013; 13(1): 37-43.

G Callea,  R. Tarricone, R Mujica Mota. The economic impact of a medical device company’s location in Italy.  Journal of medical marketing 2013; 13(1): 24-36.

R. Tarricone. Setting the Scene: The Challenges of Universal Health Coverage and the Contribution of Management Education. Value in Health 2013; 16(1 suppl):S4-S6

M. Drummond, R. Tarricone, A. Torbica. Assessing the added value of health technologies: reconciling different perspectives. Value in Health 2013; 16(1 suppl): S7-S13.

R. Tarricone, A. Torbica. Costing and performance in healthcare management. Faltin, F.W, Kenett, R.S., Ruggeri, F. (editors) Statistical methods in healthcare. Wiley, UK, 2012, pp.386-404.

G. Callea, R. Tarricone, A. Medina Lara. Economic evidence of interventions for acute myocardial infarction: a review of the literature. EUROINTERVENTION 2012;8:P71-P76.

R. Mujica-Mota, R. Tarricone, O. Ciani, J.F.P. Bridges, M. Drummond. Determinants of demand for total hip and and knee arthroplasty: a systematic literature review. BMC Health Services Research 2012;12:225-257.

O. Ciani, R. Tarricone, A. Torbica. Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? Health Policy 2012; 108(2-3):194-202.

R. Tarricone (a cura di). Politiche per la salute e scelte aziendali. Impatto sull’innovazione e diffusione delle tecnologie mediche. EGEA, 2012.

A. Compagni, A. Melegaro, R. Tarricone. Systematic review of the economic literature on genetic testing for the prevention of venous thromboembolism. Italian Journal of Public Health 2012;9:s36-s45.

R. Tarricone, M. Drummond. Challenges in the clinical and economic evaluation of medical devices: the case of transcathether aortic valve implantation. Journal of Medical Marketing 2012;11:221-229.

R. Tarricone. Pharmaco-economics and decision making in health care. The case of “extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis”. Internal and Emergency Medicine 2011;6:581-582.

C Sorenson, R Tarricone, M Siebert, M Drummond. Applying Health Economics for Policy Decision Making: Do Devices Differ From Drugs? EUROPACE 2011;13:ii54-ii58.

R. Tarricone. Innovazione e competitività dei sistemi industriali regolati. le imprese dei dispositivi medici. EGEA, 2010.

R. Tarricone, A. Torbica, F. Franzetti, V.D. Rosenthal. Hospital cost of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. Cost Effectiveness and Resource Allocation 2012;8:1-10.

Aguzzi G, Bartoli S, Tarricone R. Systematic review of urinary incontinence and overactive bladder cost-of-illness studies. The Open Pharmacoeconomics & Health Economics Journal 2010;2:11-24.

Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. UROLOGY 2010;75:491-500.

M. Drummond, A. Griffin, R. Tarricone. Economic evaluation for devices and drugs. Same or different? Value in Health 2009; 12(4):402-404.

R. Tarricone, A. Tsouros. Homecare in Europe. The solid facts. WHO, 2008

R. Tarricone, G. Aguzzi, A. Capone, et al. How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals. Journal of Medical Economics 2008; 11:265-279.

R. Tarricone, G. Aguzzi, F. Musì, L. Fariselli, A. Casasco. Cost-effectiveness for trigeminal neuralgia: Cyberknife vs microvascular decompression. Neuropsychiatric Disease and Treatment 2008; 4(3):647-652.

P. Roggero, R. Tarricone, V. Mangiaterra, et al. What do people think about disabled youth and employment in developing and developed countries? Results from an e-discussion hosted by the World Bank. Disability and Society 2006;21(6):645-650

R. Tarricone. COI analysis: what room in health economics? Health Policy 2006;77(1):51-63

R. Tarricone, F. Girolami. Economic evaluation of a new antiemetic drug: palonosetron vs ondansetron. Clinical Drug Investigation 2005; 25(9):597-608.

S. Gerzeli, R. Tarricone, P. Zolo, et al. The economic burden of stroke in Italy. The EcLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation. Neurological Science 2005; 26(2):72-80.

R. Tarricone, Valutazioni economiche e management in sanità. Applicazioni ai programmi e tecnologie sanitarie, Milano, McGraw-Hill, 2004.

B. Heller, R. Tarricone Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Current Medical Research and Opinion 2004;20(8):1279-1290

JA Gillette, R. Tarricone Economic Evaluation of osteoarthritis treatment in Europe. Expert Opinion 2003; 4(3):327-341

R. Tarricone,  E. Martelli, F. Parazzini,  J. Darbà,  C. Le Pen,  J. Rovira, "Economic Evaluation of Nimesulide Versus Diclofenac in the Treatment of Osteoarthritis in France, Italy and Spain". Clinical Drug Investigation 2001;21(7): 453-464

G. Fattore,  S. Gerzeli,  R. Tarricone,  "The costs of farmacological treatment for major depression. The Italian prospective multi-centre observational incidence-based study", Pharmacoeconomics, 2000, n. 2: 167-174

R. Tarricone, S. Gerzeli, R. Montanelli,  L.  Frattura, M. Percudani, G. Racagni Direct and indirect costs of Schizophrenia in community psychiatric services in Italy. The GISIES study. Health Policy 2000; 51:1-18